Purpose: Antiangiogenic therapy is crucial for advanced hepatocellular carcinoma (HCC) treatment. Interleukin (IL)-6 is an inflammatory response mediator that can promote angiogenesis. We explored its prognostic role in patients with advanced HCC. Methods: We had two patient cohorts, both comprising patients who received sorafenib-containing therapy as the first-line treatment for advanced HCC. We explored the best cut point for pretreatment plasma IL-6 levels in the exploration cohort and then confirmed it in the validation cohort. Results: In total, 55 and 73 patients constituted the exploration and validation cohorts, respectively. In the exploration cohort, a cut point of 4.28 pg/ml was the best for defining high and low IL-6 levels because it could most effectively differentiate overall survival (OS). On application of this cut point to the validation cohort, patients with high plasma IL-6 levels, compared with patients with low IL-6 levels, exhibited significantly poorer OS (median, 8.0 vs 13.9 months, P = 0.031) but similar progression-free survival or treatment response. After adjusting for patient demographics and tumor characteristics, a high plasma IL-6 level remained an independent predictor of poor OS (hazard ratio 2.594, P = 0.005). Conclusion: High pretreatment plasma IL-6 levels were associated with poor prognosis of patients with advanced HCC.
Introduction
Sorafenib is the approved first-line therapy for advanced hepatocellular carcinoma (HCC) because it has been demonstrated to prolong patient survival (1, 2) . However, it has modest efficacy. In 2 Phase III clinical trials comparing sorafenib with a placebo for treating advanced HCC, the objective response rate of sorafenib was only 2-3%, and the survival prolongation was shorter than 3 months (1, 2) . A biomarker that can predict the prognosis or even the efficacy of sorafenib would be substantially useful.
Interleukin (IL)-6 is an essential inflammatory response mediator that can promote angiogenesis and is involved in HCC carcinogenesis (3) (4) (5) (6) (7) . Its prognostic role was reported in localized HCC, with high serum IL-6 levels associated with recurrence and short survival after locoregional therapy (8) (9) (10) . However, the prognostic role of plasma IL-6 levels has not been well studied in patients who received sorafenib for advanced HCC. Because one of the major anticancer mechanisms of sorafenib is antiangiogenesis (11) , the associations between plasma IL-6 levels and the prognosis of patients with advanced HCC are worth exploration.
Most previous biomarker studies on advanced HCC lacked validation cohorts. Although blood levels of angiopoietin-2, hepatocyte growth factor, insulin-like growth factor-1 and transforming growth factor-β1 have shown potential as biomarkers for advanced HCC patients treated with sorafenib (12) (13) (14) (15) (16) (17) , these studies had only one exploration cohort and their results remained to be validated. We had collected two separate patient cohorts, both comprising patients who received sorafenib-containing therapy as first-line therapy for advanced HCC, we thus planned this study to explore the prognostic role of plasma IL-6 levels.
Materials and methods

Study population
We established two prospective patient cohorts, both of which consisted of patients who received sorafenib-containing therapy for advanced HCC. We used one cohort as the exploration cohort and the other as the validation cohort. The exploration cohort consisted of patients who were previously enrolled in the original and expansion cohorts of a Phase II clinical trial conducted at the National Taiwan University Hospital (NTUH), Taipei, Taiwan, and agreed to undergo pretreatment peripheral blood collection. The aforementioned clinical trial tested a first-line combination systemic therapy comprising sorafenib with metronomic chemotherapy for advanced HCC; metronomic therapy was defined as the uninterrupted administration of low-dose chemotherapeutic agents over a prolonged period (18) . All patients were required to have adequate liver reserve (Child-Pugh Class A) and organ function. The results of that clinical trial have been published (19) .
The validation cohort consisted of patients who received sorafenib alone as the first-line therapy for advanced HCC, under reimbursement by the National Health Insurance (NHI), Taiwan, and agreed to undergo peripheral blood collection. According to NHI regulations, all patients were required to have Child-Pugh A liver reserve and HCC that had either extrahepatic metastasis or macrovascular invasion. An application containing patients' clinical data must be submitted for approval before treatment initiation and every 8 weeks after that to ensure that the disease had not progressed. This biomarker study was approved by the Research Ethical Committee of NTUH.
Plasma IL-6 measurement
Blood samples were carefully layered onto Histopaque-1077 ® (Sigma, St. Louis, MO, USA) and then centrifuged at 400 × g (relative centrifugal force) for 30 min at 4°C. The plasma was separated and stored at −80°C. The IL-6 levels of the plasma samples were determined through an enzyme-linked immunosorbent assay (R&D, Minneapolis, MN, USA).
Statistical methods
In the exploration cohort, we used the receiver operating characteristic (ROC) curve to determine the cut point of plasma IL-6 levels that could provide the highest sensitivity and specificity for predicting individual overall survival (OS) that was shorter than the median OS. We then used the cut point to define high (>median) and low (≤median) plasma IL-6 levels for analysis of the validation cohort.
The Kaplan-Meier method was used to estimate survival, and the log-rank test was used in a univariate analysis to compare survival between groups. For multivariate analysis, a Cox proportional hazards model was used to adjust for age, gender, hepatitis etiology, macrovascular invasion, extrahepatic spread, α-fetoprotein levels >400 ng/ml, Eastern Cooperative Oncology Group (ECOG) performance status, and prior HCC treatment. The stepwise variable selection procedure was used during the multivariate analysis, with the significance levels for entry and stay set at 0.15 or higher. To examine the associations between plasma IL-6 levels and patient characteristics, the chi-squared test (and Fisher exact test, when appropriate) was used for nominal variables, and the independent t test was used for continuous variables. The chi-squared test was also used to evaluate the association between plasma IL-6 levels and treatment response (complete or partial response) or disease control (complete response + partial response + stable disease). All statistical analyses were performed using SAS statistical software (version 9.1.3, The SAS Institute, Cary, NC, USA). A two-sided P value of ≤0.05 was considered statistically significant.
Results
Patient characteristics and treatment outcomes
The exploration and validation cohorts had 55 and 73 patients, respectively. Basic patient characteristics are listed in Table 1 . Hepatitis B virus was the predominant hepatitis etiology, leading to disease in 76% and 64% of the patients from the exploration and validation cohorts, respectively. All patients from the exploration cohort had Child-Pugh A liver reserve, whereas 88% of those from the validation cohort had Child-Pugh A liver reserve. The distribution of Cancer of the Liver Italian Program (CLIP) scores was similar in the two cohorts, with~40% of patients having CLIP scores of ≥3. Only 56% of patients from the exploration cohort had received prior HCC treatment, as opposed to 80% from the validation cohort.
In the exploration cohort, no complete response and 3 (6%) partial responses were observed. The median OS was 8.1 (95% confidence interval [CI], 3.8-12.4) months. In the validation cohort, no complete response and 7 (10%) partial responses were observed. The median OS was 10.3 (95% CI, 6.2-14.5) months.
Exploration of cut points for plasma IL-6 level
To predict OS, we used the ROC curve to decide the best cut point for plasma IL-6 levels in the exploration cohort. A cut point of 4.28 pg/ml resulted in the highest sensitivity (67.9%) and specificity (55.6%; Fig. 1A ). In the exploration cohort, patients with high (>4.28 pg/ml) pretreatment plasma IL-6 levels exhibited poorer OS than did patients with low (≤4.28 pg/ml) plasma IL-6 levels (median OS, 6.1 vs 14.8 months, P = 0.042; Fig. 1B) .
Validation of cut points of plasma IL-6 levels
Subsequently, we used the same cut point for IL-6 levels to analyze patients in the validation cohort. Patients with high pretreatment plasma IL-6 levels exhibited significantly poorer OS than did patients with low IL-6 levels (median, 8.0 vs 13.9 months, P = 0.031; Fig. 2A) . A multivariate analysis adjusting for age, gender, hepatitis etiology, macrovascular invasion, extrahepatic spread, α-fetoprotein level >400 ng/ml, Eastern Cooperative Oncology Group (ECOG) performance status and prior HCC treatment showed that a high plasma IL-6 level was an independent predictor of poorer OS (hazard ratio 2.594, P = 0.005; Table 2 ). By contrast, plasma IL-6 levels were not associated with progression-free survival (PFS; P = 0.460, Fig. 2B ) or time to progression (TTP; P = 0.607, Fig. 2C ).
Plasma IL-6 levels and patient characteristics
We analyzed whether plasma IL-6 levels were correlated with other potential prognostic factors, and found that plasma IL-6 levels were not associated with patients' age, gender, hepatitis etiology, The Kaplan-Meier curve showing the OS of patients from the exploration cohort, grouped by their pretreatment IL-6 levels which was dichotomized using the cut point (4.28 pg/ml) found in Fig. 1 . The P value was calculated using the log-rank test. , and (C) time to progression (TTP) of patients from the validation cohort, grouped by with high and low pretreatment interleukin (IL)-6 levels. The high and low IL-6 levels were determined using the cut point (4.28 pg/ml) found in the exploration cohort. P values were calculated using the log rank test. macrovascular invasion, extrahepatic spread, α-fetoprotein level, serum albumin level, platelet count, Child-Pugh status, Barcelona Clinic Liver Cancer stage, CLIP scores or performance status (Table 3 ). In addition, plasma IL-6 levels failed to predict treatment response (P = 1.000) or disease control (P = 0.356; Table 3 ).
Discussion
In this study, high pretreatment plasma IL-6 levels were associated with poor OS in patients who received sorafenib as the first-line systemic therapy for advanced HCC. The cut point for IL-6 levels (4.28 pg/ml) was identified in the exploration cohort and confirmed in the validation cohort. In addition, a high plasma IL-6 level remained an independent predictor of poor OS, even after adjusting for multiple patient and tumor characteristics in the multivariate analysis.
Contrary to their prognostic role, plasma IL-6 levels could not predict the efficacy of sorafenib because they were not associated with PFS, TTP, treatment response, or disease control in our study. High serum IL-6 levels have been shown to be associated with disease recurrence after locoregional therapy for HCC (8) (9) (10) . Our study corroborates these previous reports in supporting the prognostic significance of IL-6 levels in various stages of HCC. By contrast, our results did not support the important role of plasma IL-6 in predicting the efficacy of sorafenib for HCC.
A previous study examining a first-line therapy using thalidomide and tegafur/uracil for patients with advanced HCC identified a prognostic role of blood IL-6 levels (20) . Additionally, the study reported that patients with high IL-6 levels had poor PFS. Similar findings regarding IL-6 levels were also observed in patients who received different first-line therapies, thereby confirming the prognostic role of plasma IL-6 levels in patients with advanced HCC. Because both thalidomide and sorafenib had antiangiogenic effects (21, 22) , whether plasma IL-6 levels can predict the prognosis of patients with advanced HCC who receive therapies of completely different mechanisms, such as immunotherapy, should be explored. IL-6 is a mediator of inflammation response, which may lead to venous metastases, recurrence and prognosis of HCC (23) . High serum IL-6 levels have been associated with large tumor sizes, advanced tumor stages, and recurrence or short survival after locoregional therapy for HCC (8) (9) (10) . The cut points (3.7-10 pg/ml) used in these studies are comparable to those used in our study. Although we did not find associations between plasma IL-6 levels and any characteristics of our HCC patients, IL-6 might still play a role in the progression of HCC.
These results reinforce our findings and imply that IL-6 plays a role in the recurrence or progression of HCC. For example, Wan et al. revealed that tumor-associated macrophages produced IL-6 to promote the proliferation of HCC stem cells (5) . Whether therapy against IL-6 signaling could be an effective HCC treatment awaits exploration.
Although both the cohorts in this study were prospective cohorts, the validation cohort did not belong to a clinical trial but was an observational cohort. Therefore, the treatment and tumor assessment in this cohort may not have been as standardized as those in clinical trial settings. However, these patients were receiving sorafenib under reimbursement by the NHI of Taiwan, which has very strict regulations for sorafenib therapy. Sorafenib use must be approved in advance and reviewed every 2 months to ensure no disease progression under treatment. Therefore, we believe that the treatment and follow-up of these patients were still adequate.
PFS and TTP might not be the perfect surrogate markers for OS in patients who received targeted therapy for advanced HCC. We found that IL-6 levels had different association with OS and TTP or PFS. A recent study found that post-progression survival was a stronger predictor for OS than PFS in patients with advanced HCC (24) . Similarly, another study also only identified modest correlation between TTP and OS in patients with advanced HCC (25) .
In conclusion, we demonstrated that high pretreatment plasma IL-6 levels were associated with poor OS in patients who received sorafenib for advanced HCC. 
